Although previous reports show that CpG ODNs and IL-21 produce superior anti-CLL cell activity when combined in vitro, the mechanism by which CpG ODNs induce IL21R and thereby enhance its effects has hitherto not been elucidated. The gene discussed is IL21; the disease is B-cell chronic lymphocytic leukemia.